As of 2026-03-18, the EV/EBITDA ratio of Bolt Biotherapeutics Inc (BOLT) is 0.21. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. BOLT's latest enterprise value is -9.23 mil USD. BOLT's TTM EBITDA according to its financial statements is -43.08 mil USD. Dividing these 2 quantities gives us the above BOLT EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.5x - 17.9x | 14.7x |
| Forward P/E multiples | 17.6x - 22.5x | 20.3x |
| Fair Price | (385.21) - (392.39) | (383.42) |
| Upside | -8776.0% - -8937.7% | -8735.6% |
| Date | EV/EBITDA |
| 2026-03-17 | 0.20 |
| 2026-03-16 | 0.21 |
| 2026-03-13 | 0.24 |
| 2026-03-12 | 0.23 |
| 2026-03-11 | 0.23 |
| 2026-03-10 | 0.22 |
| 2026-03-09 | 0.23 |
| 2026-03-06 | 0.22 |
| 2026-03-05 | 0.22 |
| 2026-03-04 | 0.21 |
| 2026-03-03 | 0.22 |
| 2026-03-02 | 0.21 |
| 2026-02-27 | 0.21 |
| 2026-02-26 | 0.21 |
| 2026-02-25 | 0.19 |
| 2026-02-24 | 0.19 |
| 2026-02-23 | 0.19 |
| 2026-02-20 | 0.19 |
| 2026-02-19 | 0.18 |
| 2026-02-18 | 0.20 |
| 2026-02-17 | 0.19 |
| 2026-02-13 | 0.19 |
| 2026-02-12 | 0.19 |
| 2026-02-11 | 0.19 |
| 2026-02-10 | 0.19 |
| 2026-02-09 | 0.18 |
| 2026-02-06 | 0.15 |
| 2026-02-05 | 0.17 |
| 2026-02-04 | 0.17 |
| 2026-02-03 | 0.15 |
| 2026-02-02 | 0.15 |
| 2026-01-30 | 0.15 |
| 2026-01-29 | 0.13 |
| 2026-01-28 | 0.11 |
| 2026-01-27 | 0.10 |
| 2026-01-26 | 0.12 |
| 2026-01-23 | 0.11 |
| 2026-01-22 | 0.13 |
| 2026-01-21 | 0.13 |
| 2026-01-20 | 0.13 |
| 2026-01-16 | 0.13 |
| 2026-01-15 | 0.10 |
| 2026-01-14 | 0.12 |
| 2026-01-13 | 0.15 |
| 2026-01-12 | 0.15 |
| 2026-01-09 | 0.15 |
| 2026-01-08 | 0.15 |
| 2026-01-07 | 0.15 |
| 2026-01-06 | 0.15 |
| 2026-01-05 | 0.16 |